Tyra Biosciences
TYRA
51 hedge funds and large institutions have $573M invested in Tyra Biosciences in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 5 closing their positions.
114% more capital invested
Capital invested by funds: $268M → $573M (+$305M)
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 46 → 51 (+5)
0.5% more ownership
Funds ownership: 83.51% → 84.01% (+0.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.13M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.33M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$1.11M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$573K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.7M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.16M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$276K |
| 4 |
D.E. Shaw & Co
New York
|
-$251K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$203K |
TYRA Hedge Fund Activity: Q1 2023 in Review
51 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2023, worth a combined $573M — up 114% from $268M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TYRA positions and 5 closed out — a net gain of 5 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was BVF Inc, adding an estimated $9.13M. The largest seller was Fidelity Investments, cutting an estimated $8.7M.
- 51 institutional investors held Tyra Biosciences (TYRA) as of Q1 2023, up from 46 in Q4 2022.
- Funds reported $573M of Tyra Biosciences stock for Q1 2023, up 114% quarter-over-quarter.
- 10 funds opened new Tyra Biosciences positions in Q1 2023 and 5 closed out, a net change of +5 holders.
- The largest Tyra Biosciences buyer in Q1 2023 was BVF Inc, an estimated $9.13M added.
- The largest Tyra Biosciences seller in Q1 2023 was Fidelity Investments, an estimated $8.7M sold.
Based on aggregated 13F filings for Q1 2023.